First Clinical Trial Confirms Kratom Significantly Inhibits CYP3A Enzyme, Raising Drug Interaction Concerns

Why it matters

Millions of Americans take medications metabolized by the CYP3A enzyme — including common drugs for heart conditions, HIV, cancer, and psychiatric disorders. This first human clinical study confirming kratom inhibits CYP3A means co-use could cause dangerous drug accumulation and toxicity in people who take these medications.

The big picture

While laboratory studies had long suggested kratom alkaloids might inhibit the CYP3A enzyme system — which metabolizes roughly 50% of all prescription drugs — this is the first published clinical study in humans to confirm the effect using a validated probe drug approach. Researchers measured the pharmacokinetics of midazolam, a standard CYP3A probe substrate, in regular kratom users. The paper was published February 24, 2026, in Clinical Pharmacology & Therapeutics, one of the leading journals in drug metabolism science.

Key findings

• A clinical trial published in Clinical Pharmacology & Therapeutics confirmed that kratom inhibits CYP3A activity in humans using midazolam as a validated probe substrate
• CYP3A enzymes metabolize approximately 50% of all prescription and over-the-counter drugs, including opioids, benzodiazepines, statins, antiretrovirals, and many cancer medications
• This is the first in-human clinical study confirming this pharmacokinetic interaction — prior evidence came only from in vitro laboratory experiments
• Elevated blood levels of CYP3A-metabolized drugs due to kratom inhibition could increase the risk of serious adverse effects or toxicity
• The finding has direct implications for clinicians treating patients who use kratom alongside prescription medications

What they say

The study authors noted that their clinical study showed "kratom inhibits CYP3A activity using midazolam as the probe substrate" — underscoring the need for healthcare providers to screen patients for kratom use when prescribing drugs metabolized through the CYP3A pathway.

Bottom line

The first human clinical trial confirms kratom is a CYP3A inhibitor — meaning it may significantly raise blood levels of dozens of common medications and increase the risk of toxicity, making it essential for clinicians to ask patients about kratom use.